Safety evaluation of a recombinant plasmin derivative lacking kringles 2–5 and rt-PA in a rat model of transient ischemic stroke

BACKGROUND: Tissue type plasminogen activator is the only approved thrombolytic agent for the treatment of ischemic stroke. However, it carries the disadvantage of a 10-fold increase in symptomatic and asymptomatic intracranial hemorrhage. A safer thrombolytic agent may improve patient prognosis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Crumrine, R Christian, Marder, Victor J, Taylor, G McLeod, LaManna, Joseph C, Tsipis, Constantinos P, Novokhatny, Valery, Scuderi, Philip, Petteway, Stephen R, Arora, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464715/
https://www.ncbi.nlm.nih.gov/pubmed/22591588
http://dx.doi.org/10.1186/2040-7378-4-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464715/
https://www.ncbi.nlm.nih.gov/pubmed/22591588
http://dx.doi.org/10.1186/2040-7378-4-10

Ejemplares similares